Homocysteine as a Predictor Tool in Multiple Sclerosis.

Discoveries (Craiova, Romania) Pub Date : 2021-09-28 eCollection Date: 2021-07-01 DOI:10.15190/d.2021.14
Radu Razvan Mititelu, Carmen Valeria Albu, Manuela Violeta Bacanoiu, Vlad Padureanu, Rodica Padureanu, Gabriela Olaru, Ana-Maria Buga, Maria Balasoiu
{"title":"Homocysteine as a Predictor Tool in Multiple Sclerosis.","authors":"Radu Razvan Mititelu,&nbsp;Carmen Valeria Albu,&nbsp;Manuela Violeta Bacanoiu,&nbsp;Vlad Padureanu,&nbsp;Rodica Padureanu,&nbsp;Gabriela Olaru,&nbsp;Ana-Maria Buga,&nbsp;Maria Balasoiu","doi":"10.15190/d.2021.14","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a progressive and irreversible disease which affects the central nervous system (CNS) with still unknown etiology. Our study aimes to establish the homocysteine pattern that can predict the MS diseases progression and to identify a potential disease progression marker that can be easy to perform and non-invasive, in order to predict the diseases outcome. In order to achieve this goal, we included 10 adult RRMS subjects, 10 adult SPMS subjects and 10 age-matched healthy subjects. The homocysteine plasma level was measured using automated latex enhanced immunoassay and the cobalamin and folate measurements were performed using automated chemiluminescence immunoassay (CLIA). HCR was calculated by dividing the homocysteine plasma level by cobalamin plasma level. We found that the homocysteine level in plasma of both RRMS patients and SPMS group are significantly increased compared with the control group. There is a significantly higher concentration of homocysteine in SPMS group compared with the RRMS group. In addition, the HCR is significantly increased in SPMS compared with the RRMS group and is a very good index of disease severity.</p>","PeriodicalId":72829,"journal":{"name":"Discoveries (Craiova, Romania)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601869/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discoveries (Craiova, Romania)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15190/d.2021.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Multiple sclerosis (MS) is a progressive and irreversible disease which affects the central nervous system (CNS) with still unknown etiology. Our study aimes to establish the homocysteine pattern that can predict the MS diseases progression and to identify a potential disease progression marker that can be easy to perform and non-invasive, in order to predict the diseases outcome. In order to achieve this goal, we included 10 adult RRMS subjects, 10 adult SPMS subjects and 10 age-matched healthy subjects. The homocysteine plasma level was measured using automated latex enhanced immunoassay and the cobalamin and folate measurements were performed using automated chemiluminescence immunoassay (CLIA). HCR was calculated by dividing the homocysteine plasma level by cobalamin plasma level. We found that the homocysteine level in plasma of both RRMS patients and SPMS group are significantly increased compared with the control group. There is a significantly higher concentration of homocysteine in SPMS group compared with the RRMS group. In addition, the HCR is significantly increased in SPMS compared with the RRMS group and is a very good index of disease severity.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
同型半胱氨酸作为多发性硬化症的预测工具。
多发性硬化症(MS)是一种进行性和不可逆的疾病,影响中枢神经系统(CNS),病因尚不清楚。我们的研究旨在建立可以预测多发性硬化症疾病进展的同型半胱氨酸模式,并确定一种易于执行且无创的潜在疾病进展标志物,以预测疾病结果。为了实现这一目标,我们纳入了10名成人RRMS受试者、10名成人SPMS受试者和10名年龄匹配的健康受试者。使用自动乳胶增强免疫测定法测定同型半胱氨酸血浆水平,使用自动化学发光免疫测定法(CLIA)测定钴胺素和叶酸。通过将同型半胱氨酸血浆水平除以钴胺素血浆水平来计算HCR。我们发现,与对照组相比,RRMS患者和SPMS组的血浆同型半胱氨酸水平均显著升高。SPMS组的同型半胱氨酸浓度明显高于RRMS组。此外,与RRMS组相比,SPMS组的HCR显著增加,是一个非常好的疾病严重程度指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Impact of Dementia on Patients with Hip Fracture. Discovery that cells have plasma membrane portals called porosomes that govern secretion. Impact of the reporting source on Platelet Inhibition and Treatment Outcomes (PLATO) trial deaths. High Sensitivity C-Reactive Protein as a Prognostic Indicator of Cardiovascular Disease in Severe Non-Diabetic COVID-19 Patients. Cardiac Involvement in Monkeypox Outbreak.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1